SEARCH:   Advanced

Blood, 15 April 2006, Vol. 107, No. 8, pp. 3288-3294. Prepublished online as a Blood First Edition Paper on December 20, 2005; DOI 10.1182/blood-2005-10-4048. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-10-4048v1 107/8/3288    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kaufman, Y. Articles by Assaraf, Y. G. Search for Related Content PubMed PubMed Citation Articles by Kaufman, Y. Articles by Assaraf, Y. G. Related Collections Oncogenes and Tumor Suppressors Gene Expression Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss Yotam Kaufman, Ilan Ifergan, Lilah Rothem, Gerrit Jansen, and Yehuda G. Assaraf From the Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel; and Department of Rheumatology, University Hospital, Vrije Universiteit (VU), Amsterdam, The Netherlands. The reduced folate carrier (RFC) is the dominant route for the uptake of various antifolates including PT523, a potent dihydrofolate reductase inhibitor (Ki = 0.35 pM) and an excellent transport substrate of the RFC (Kt = 0.7 µM). Here, we describe the multiple mechanisms of RFC inactivation in human leukemia PT523-resistant cells originally harboring 3 RFC alleles. Cellular exposure to gradually increasing PT523 concentrations resulted in sublines displaying up to 3500-fold resistance to various hydrophilic antifolates that rely on RFC for their cellular uptake. Antifolate-resistant cells lost RFC gene expression (65%-99% loss) due to impaired promoter binding of various transcription factors that regulate RFC gene expression. Additionally, DNA sequencing revealed that PT523-resistant cells contained a cluster of 4 nearly consecutive mutations residing on a single RFC allele including L143P, A147V, R148G, and Q150Stop. Southern blot analysis established the loss of an RFC allele in PT523-resistant cells. These alterations resulted in markedly decreased RFC protein levels (80%-99% loss) and consequently impaired [3H]methotrexate transport (87%-99% loss). This study provides the first evidence that acquisition of PT523 resistance in human leukemia cells harboring 3 RFC alleles is due to multiple coexisting alterations including transcriptional silencing, inactivating mutations, and RFC allele loss. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Balamurugan, B. Ashokkumar, M. Moussaif, J. Y. Sze, and H. M. Said Cloning and functional characterization of a folate transporter from the nematode Caenorhabditis elegans Am J Physiol Cell Physiol, August 1, 2007; 293(2): C670 - C681. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020